Semaglutide, as a large 31-amino-acid peptide analog, has essentially no structural similarity to the small-molecule controlled substances targeted by standard drug panels
The timeline below isn't intended to predict results
Retatrutide is generally given via a weekly injection (just like most other GLP-1)
S2088 Glucagon-like peptide-1 receptor agonist-associated colonic ischemia: A case report
Most common GLP-1 side effects The most common side effects of Semaglutide (GLP-1) medications include nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, abdominal distension, eructation (belching), hypoglycemia (low blood sugar) in patients with type 2 diabetes, flatulence (gas buildup), gastroenteritis (an intestinal infection), and gastroesophageal reflux disease (a type of digestive disorder)